Clinical Ink Merges with CentrosHealth
Clinical Ink, an early provider of eSource solutions for clinical trials, announced a merger with CentrosHealth, a provider of configurable mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO) founded by MPM Capital. The resulting eSource platform for research sites, provides sponsors with the ability to receive all of their data, both from the site and the patient, in real-time and can reduce the cost, time, and complexity of the clinical trial process. The Clinical Ink approach to eSource and mobile data capture has been endorsed by both FDA and EMA and is an integral component of novel ‘risk-based monitoring’ approaches to clinical research oversight.
Further, Clinical Ink entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials. Clinical Ink also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for Clinical Ink to expand operational capabilities and further develop its paperless clinical trial platform.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
